One might think that as the understanding of science grows, it would be easier to create new prescription drugs. But in reality, that’s what can make it harder.
The attempt to make new effective medication quite often ends in failure. As PhRMA pointed out, just 12 percent of drugs entering clinical trials ever making it to patients. Not only that, thousands won’t even make it past the early discovery and pre-clinical testing stages.
As it was stated via PR Newswire:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biology isn’t rocket science. It’s harder than rocket science. Each living thing is an amazingly complex system and each interacts with other living things in complex ways. That is why discovering and developing new treatment and cures is such a complex and risky undertaking. On average, it takes more than 10 years for just one medicine to make its way through the entire R&D process. And the average cost to develop just one medicine has risen to $2.6 billion.
The good news is, even though the odds aren’t great and it’s costly, people are still desperately trying to find treatment for diseases like Alzheimer’s and forms cancer, among so many others. There are currently more than 7,000 medicines in development around the world, according to PhRMA.
Many tenacious people keep the ball rolling, thankfully.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Photo: Flickr user reynermedia
